Current Perspectives of Anticoagulation in Patients With COVID-19

被引：17
作者：
Gavioli, Elizabeth M. [1 ]
Sikorska, Gabriela [1 ]
Man, Ammy [1 ]
Rana, Jay [1 ]
Vider, Etty [1 ,2 ]
机构：
[1] Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Div Pharm, Brooklyn, NY USA
[2] Brookdale Hosp, Med Ctr, Div Pharm, Brooklyn, NY USA
来源：
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | 2020年 / 76卷 / 02期
关键词：
SARS-CoV-2; COVID-19; thromboembolism; anticoagulation; MANAGEMENT; DISEASE;
D O I：
10.1097/FJC.0000000000000861
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.
引用
收藏
页码：146 / 150
页数：5
相关论文
共 50 条
  • [31] Prothrombotic Milieu, Thrombotic Events and Prophylactic Anticoagulation in Hospitalized COVID-19 Positive Patients: A Review
    Cryer, Michael Joseph
    Farhan, Serdar
    Kaufmann, Christoph C.
    Jaeger, Bernhard
    Garg, Aakash
    Krishnan, Prakash
    Mehran, Roxana
    Huber, Kurt
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [32] Anticoagulation in COVID-19: why, what, and when
    Taema, Khaled M.
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2021, 70 (05): : 12 - 15
  • [33] COVID-19 and Its Implications for Thrombosis and Anticoagulation
    Berkman, Samuel A.
    Tapson, Victor F.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 42 (02) : 316 - 326
  • [34] Anticoagulation in COVID-19: not strong for too long?
    Tacquard, Charles
    Mansour, Alexandre
    Godon, Alexandre
    Gruel, Yves
    Susen, Sophie
    Godier, Anne
    Albaladejo, Pierre
    ANAESTHESIA CRITICAL CARE & PAIN MEDICINE, 2021, 40 (02)
  • [35] COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations
    Levy, Jerrold H.
    Iba, Toshiaki
    Olson, Lyra B.
    Corey, Kristen M.
    Ghadimi, Kamrouz
    Connors, Jean M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 : 29 - 35
  • [36] COVID-19 and the cardiovascular system-current knowledge and future perspectives
    Chatzis, Dimitrios G.
    Magounaki, Kalliopi
    Pantazopoulos, Ioannis
    Bhaskar, Sonu Menachem Maimonides
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (27) : 9602 - 9610
  • [37] COVID-19 in Southeast Asia: current status and perspectives
    Dinh-Toi Chu
    Suong-Mai Vu Ngoc
    Hue Vu Thi
    Yen-Vy Nguyen Thi
    Thuy-Tien Ho
    Van-Thuan Hoang
    Singh, Vijai
    Al-Tawfiq, Jaffar A.
    BIOENGINEERED, 2022, 13 (02) : 3797 - 3809
  • [38] Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism
    Prince, Martin R.
    Dev, Hreedi
    Lane, Elizabeth G.
    Margolis, Daniel J.
    DeSancho, Maria T.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 54 (03) : 431 - 437
  • [39] Periprocedural Bridging Anticoagulation: Current Perspectives
    Palaniswamy, Chandrasekar
    Selvaraj, Dhana R.
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (04) : E89 - E94
  • [40] Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients
    Gabara, C.
    Solarat, B.
    Castro, P.
    Fernandez, S.
    Badia, J. R.
    Toapanta, D.
    Schulman, S.
    Reverter, J. C.
    Soriano, A.
    Moises, J.
    Aibar, J.
    MEDICINA INTENSIVA, 2023, 47 (01) : 1 - 8
12345